Recent progress in the discovery and development of stearoyl CoA desaturase inhibitors

Chemistry and Physics of Lipids

Volumn 197, Issue , 2016, Pages 3-12

  Uto, Yoshikazu ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Acne; Cancer; Nonalcoholic steatohepatitis (NASH); Skin disorders; Stearoyl CoA desaturase 1 (SCD1)

Indexed keywords

A 939572; ACYL COENZYME A DESATURASE; ACYL COENZYME A DESATURASE INHIBITOR; ENZYME INHIBITOR; ISOXAZOLE DERIVATIVE; UNCLASSIFIED DRUG; XEN 103;

ALZHEIMER DISEASE; BODY WEIGHT; DERMATOLOGY; HEPATITIS C; HUMAN; LIPID METABOLISM; LIVER; NEOPLASM; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN DISEASE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; PATHOLOGY; SKIN;

ANIMALS; DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS; LIVER; NEOPLASMS; SKIN; STEAROYL-COA DESATURASE;

EID: 84960802555     PISSN: 00093084     EISSN: 18732941     Source Type: Journal    
DOI: 10.1016/j.chemphyslip.2015.08.018     Document Type: Article

References (86)

1. G. Alvisi, V. Madan, and R. Bartenschlager Hepatitis C virus and host cell lipids: an intimate connection RNA Biol. 8 2011 258 269
2. F.Z. Aly, and D.E. Kleiner Update on fatty liver disease and steatohepatitis Adv. Anat. Pathol. 18 2011 294 300
3. B. Anick, A. Laurent, K. Gideon, B. Lucie, P. Sylvie, and O. Driss Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective Brit J. Clin. Pharmacol. 63 2007 196 205
4. G. Astarita, K.M. Jung, V. Vasilevko, N.V. Dipatrizio, S.K. Martin, D.H. Cribbs, E. Head, C.W. Cotman, and D. Piomelli Elevated stearoyl-CoA desaturase in brains of patients with Alzheimer's disease PLoS One 6 10 2011 e24777
5. A.D. Attie, R.M. Krauss, M.P. Gray-Keller, A. Brownlie, M. Miyazaki, J.J. Kastelein, A.J. Lusis, A.F.H. Stalenhoef, J.P. Stoehr, M.R. Hayden, and J.M. Ntambi Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia J. Lipid Res. 43 2002 1899 1907
6. S. Bansal, M. Berk, N. Alkhouri, D.A. Partrick, J.J. Fung, and A. Feldstein Stearoyl-CoA desaturase plays an important role in proliferation and chemoresistance in human hepatocellular carcinoma J. Surg. Res. 186 2014 29 38
7. Bartel, P.L., Roch, J-M., Sugiyama, J., 2007. Myriad Genetics, Inc. Therapeutic methods, compounds and compositions US20070087363.
8. J. Brugarolas Molecular genetics of clear-cell renal cell carcinoma J. Clin. Oncol. 32 2014 1968 1976
9. L. Byberg, L. Kilander, E.W. Lemming, K. Michaelsson, and B. Vessby Cancer death is related to high palmitoleic acid in serum and to polymorphisms in the SCD-1 gene in healthy Swedish men Am. J. Clin. Nutr. 99 2014 551 558
10. A. Carracedo, L.C. Cantley, and P.P. Pandolfi Cancer metabolism: fatty acid oxidation in the limelight Nat. Rev. Cancer 13 4 2013 227 232
11. R.B. Chan, T.G. Oliveira, E.P. Cortes, L.S. Honig, K.E. Duff, S.A. Small, M.R. Wenk, G. Shui, P. Di, and G. aolo Comparative lipidomic analysis of mouse and human brain with Alzheimer disease J. Biol. Chem. 287 2012 2678 2680
12. P. Dobrzyn, and A. Dobrzyn Stearoyl-CoA desaturase: a new therapeutic target of liver steatosis Drug Dev. Res. 67 2006 643 650
13. K.R. Feingold, and P.M. Elias Role of lipids in the formation and maintenance of the cutaneous permeability barrier Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1841 2014 280 294
14. M.T. Flowers, and J.M. Ntambi Role of stearoyl-coenzyme A desaturase in regulating lipid metabolism Curr. Opin. Lipidol. 19 2008 248 256
15. W.J. Harrison, J.J. Bull, H. Seltmann, and et al. Expression of lipogenic factors galectin-12, resistin, SREBP-1, and SCD in human sebacous glands and cultured sebocytes J. Invest. Dermatol. 127 2007 1309 1317
16. E. Herker, and M. Ott Unique ties between hepatitis C virus replication and intracellular lipids Trends Endocrinol. Metab. 22 2011 241 248
17. D. Hess, J.W. Chisholm, and R.A. Igal Inhibition of stearoylCoA desaturase activity blocks cell cycle progression and induces programmed cell death in lung cancer cells PLoS One 5 2010 e11394
18. A.M. Holder, A.M. Gonzalez-Angulo, H. Chen, A. Akcakanat, K.-A. Do, W.F. Symmans, L. Pusztai, G.N. Hortobagyi, G.B. Mills, and F. Meric-Bernstam High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients Breast Cancer Res. Treat. 137 2013 319 327
19. Hopf, C., Drewes, G, Ruffner, H. 2006. Treatment of neurodegenerative disease by the use of SCD4 inhibitors. WO2006015621.
20. G.-M. Huang, Q.H. Jiang, C. Cai, Q. an, M. u, S. ei, and W. hen SCD1 negatively regulates autophagy-induced cell death in human hepatocellular carcinoma through inactivation of the AMPK signaling pathway Cancer Lett. 358 2015 180 190
21. Y. Ide, M. Waki, T. Hayasaka, T. Nishio, Y. Morita, H. Tanaka, T. Sasaki, K. Koizumi, R. Matsunuma, Y. Hosokawa, H. Ogura, N. Shiiya, and M. Setou Human breast cancer tissues contain abundant phosphatidylcholine(36:1) with high stearoyl-CoA desaturase-1 expression PLoS One 8 2013 e61204
22. R.A. Igal Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell proliferation, programmed cell death and transformation to cancer Carcinogenesis 31 2010 1509 1515
23. R. Iglesias-Bartolome, and J.S. Gutkind Signaling circuitries controlling stem cell fate: to be or not to be Curr. Opin. Cell Biol. 23 2011 716 723
24. P. Khandelwal, S. Stryker, H. Chao, N. Aranibar, R.M. Lawrence, M. Madireddi, W. Zhao, L. Chen, and M.D. Reily 1H NMR-based lipidomics of rodent fur: species-specific lipid profiles and SCD1 inhibitor-related dermal toxicity J. Lipid Res. 55 2014 1366 1374
25. N. Kurikawa, T. Takagi, S. Wakimoto, Y. Uto, H. Terashima, K. Kono, T. Ogata, and J. Ohsumi A novel inhibitor of stearoyl-CoA desaturase-1 attenuates hepatic lipid accumulation, liver injury and inflammation in model of nonalcoholic steatohepatitis Biol. Pharm. Bull. 36 2013 259 267
26. S. Leger, W.C. Black, D. Deschenes, S. Dolman, J.-P. Falgueyret, M. Gagnon, S. Guiral, Z. Huang, J. Guay, Y. Leblanc, C.-S. Li, F. Massé, R. Oballa, and L. Zhang Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438) Bioorg. Med. Chem. Lett. 20 2010 499 502
27. H.K. Lerat, H.L. ammoun, I. Hainault, E. Mérour, M.R. Higgs, C. Callens, S.M. Lemon, F. Foufelle, and J.M. Pawlotsky Hepatitis C Virus proteins induce lipogenesis and defective triglyceride secretion in transgenic mice J. Biol. Chem. 284 2009 33466 33474
28. J. Li, S.-F. Ding, N.A. Habib, B.F. Fermor, C.B. Wood, and R.S. Gilmour Partial characterization of a cDNA for human stearoyl-CoA desaturase and changes in its mRNA expression in some normal and malignant tissues Int. J. Cancer 57 1994 348 352
29. G. Liu, J.K. Lynch, J. Freeman, B. Liu, Z. Xin, H. Zhao, M.D. Serby, P.R. Kym, T.S. Suhar, H.T. Smith, N. Cao, R. Yang, R.S. Janis, J.A. Krauser, S.P. Cepa, D.W. Beno, H.L. Sham, C.A. Collins, T.K. Surowy, and H.S. Camp Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors J. Med. Chem. 50 2007 3086 3100
30. G. Liu Stearoyl-CoA desaturase inhibitors: update on patented compound Expert Opin. Ther. Patents 19 2009 1169 1191
31. G. Liu Recent advances in searoyl-CoA desaturase 1 inhibitors for dyslipidemia and obesity Curr. Top. Med. Chem. 10 2010 419 433
32. R.K. Lyn, R. Singaravelu, S. Kargman, S. O'Hara, H. Chan, R. Oballa, Z. Huang, D.M. Jones, A. Ridsdale, R.S. Russell, A.W. Partridge, and J.P. Pezacki Stearoyl-CoA desaturase inhibition blocks formation of hepatitis C virus-induced specialized membranes Sci. Rep. 4 2014 4549/1 4549/11
33. W.C. Man, M. Miyazaki, K. Chu, and J.M. Ntambi Membrane topology of mouse stearoyl-CoA desaturase 1 J. Biol. Chem. 281 2006 1251 1260
34. P. Mason, B. Liang, L. Li, T. Fremgen, E. Murphy, A. Quinn, S.L. Madden, H.P. Biemann, B. Wang, A. Cohen, S. Komarnitsky, K. Jancsics, B. Hirth, C.G. Cooper, E. Lee, S. Wilson, R. Krumbholz, S. Schmid, Y. Xiang, M. Booker, J. Lillie, and K. Carter SCD1 inhibition causes cancer cell death by depleting mono-unsaturated fatty acids PLoS One 7 2012 e33823
35. J.G. Meingassner, H. Aschauer, A.P. Winiski, N. Dales, D. Yowe, M.D. Winther, Z. Zhang, A. Stuetz, and A. Billich Pharmacological inhibition of stearoyl CoA desaturase in the skin induces atrophy of the sebaceous glands J. Invest. Dermatol. 133 2013 2091 2094
36. M. Miyazaki, Y.-C. Kim, M.P. Gray-Keller, A.D. Attie, and J.M. Ntambi The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1 J. Biol. Chem. 275 2000 30132 30138
37. M. Miyazaki, W.C. Man, and J.M. Ntambi Targeted disruption of stearoyl-CoA desaturase1 gene in mice causes atrophy of sebaceous and meibomian glands and depletion of wax esters in the eyelid J. Nutr. 131 2001 2260 2268
38. M. Miyazaki, M.J. Jacobsen, W.C. Man, P. Cohen, E. Asilmaz, J.M. Friedman, and J.M. Ntambi Identification and characterization of murine SCD4, a novel heart-specific stearoyl-CoA desaturase isoform regulated by leptin and dietary factors J. Biol. Chem. 278 2003 33904 33911
39. M. Miyazaki, H. Sampath, X. Liu, M.T. Flowers, K. Chu, A. Dobrzyn, and J.M. Ntambi Stearoyl-CoA desaturase-1 deficiency attenuates obesity and insulin resistance in leptin-resistant obese mice Biochem. Biophys. Res. Commun. 380 2009 818 822
40. H. Miyoshi, K. Moriya, T. Tsutsumi, S. Shinzawa, H. Fujie, Y. Shintani, H. Fujinaga, K. Goto, T. Todoroki, T. Suzuki, T. Miyamura, Y. Matsuura, H. Yotsuyanagi, and K. Koike Pathogenesis of lipid metabolism disorder in hepatitis C: Polyunsaturated fatty acids counteract lipid alterations induced by the core protein J. Hepatol 54 2011 432 438
41. N. Mizushima, B. Levine, A.M. Cuervo, and D.J. Klionsky Autophagy fights disease through cellular self-digestion Nature 451 2008 1069 1075
42. M. Narce, J. Bellenger, M. Rialland, and S. Bellenger Recent advances on stearoyl-CoA desaturase regulation in fatty liver diseases Curr. Drug Metabol. 13 2012 1454 1463
43. L.V. Nguyen, R. Vanner, P. Dirks, and C.J. Eaves Cancer stem s: an evolving concept Nat. Rev. Cancer 12 2012 133 143
44. L.N. Nguyen, Y.-S. Lim, L.V. Pham, H.-Y. Shin, Y.-S. Kim, and S.B. Hwang Stearoyl coenzyme A desaturase 1 is associated with hepatitis C virus replication complex and regulates viral replication J. Virol. 88 2014 12311 12325
45. A. Noto, S. Raffa, V. De, C. itis, G. Roscilli, D. Malpicci, P. Coluccia, N. Di, A. apoli, A. Ricci, M.R. Giovagnoli, L. Aurisicchio, MRT, M.R. orrisi, G. Ciliberto, and ManciniR Stearoyl-CoA desaturase-1 is a key factor for lung cancer-initiating cells Cell Death Dis. 4 2013 e947
46. J.M. Ntambi, and M. Miyazaki Recent insights into stearoyl-CoA desaturase-1 Curr. Opin. Lipidol. 14 2003 255 261
47. J.M. Ntambi Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol Prog. Lipid Res. 34 1995 139 150
48. R.M. Oballa, L. Belair, W.C. Black, K.C. Bleasby, C.C. han, C. Desroches, X. Du, R. Gordon, J. Guay, S. Guiral, and et al. Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia J. Med. Chem. 54 2011 5082 5096
49. Y. Ogasawara, E. Itakura, N. Kono, N. Mizushima, H. Arai, A. Nara, T. Mizukami, and A. Yamamoto Stearoyl-CoA Desaturase 1 Activity Is Required for Autophagosome Formation J. Biol. Chem. 289 2014 23938 23950
50. J.F. Oliver, R. lde la, G. ubia, V. Rolli, M.C. Ruiz-Ruiz, M. de, G. urcia, and J.M. Murcia Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant J. Biol. Chem. 273 1998 33533 33539
51. Partridge, A., Kargman, S., Oballa, R., Chan, H., 2013. Merck Canada Inc., 2013. SCD inhibitors for the treatment of HCV. WO2013062882.
52. A. Paul Nonalcoholic fatty liver disease N. Engl. J. Med. 346 2002 1221 1231
53. A. Peter, A. Cegan, S. Wagner, R. Lehmann, N. Stefan, A. Königsrainer, I. Königsrainer, H.-U. Häring, and E. Schleicher Hepatic lipid composition and stearoyl-coenzyme A desaturase 1 mRNA expression can be estimated from plasma VLDL fatty acid ratios Clin. Chem. 55 2009 2113 2120
54. J. Pezacki, R. Singaravelu, and R. Lyn Host-virus interactions during hepatitis C virus infection: a complex and dynamic molecular biosystem Mol. BioSyst. 6 2010 1131 1142
55. D.A. Powell An overview of patented small molecule stearoyl coenzyme-A desaturase inhibitors (2009-2013) Exp. Opin. Ther. Patents 24 2013 155 175
56. H.W. Querfurth, and F.M. LaFerla Alzheimer's disease N. Engl J. Med. 362 2010 329 344
57. Y.K. Ramtohul, C. Black, C.-C. Chan, S. Crane, J. Guay, S. Guiral, Z. Huang, R. Oballa, L.-J. Xu, L. Zhang, and C.S. Li SAR and optimization of thiazole analogs as potent stearoyl- CoA desaturase inhibitors Bioorg. Med. Chem. Lett. 20 2010 1593 1597
58. B.I. Rini Temsirolimus an Inhibitor of Mammalian Target of Rapamycin Clin Cancer Res 14 2008 1286 1290
59. U.V. Roongta, J.G. Pabalan, X. Wang, R.P. Ryseck, J. Fargnoli, B.J. Henley, W.P. Yang, J. Zhu, M.T. Madireddi, R.M. Lawrence, T.W. Wong, and B.A. Rupnow Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy Mol. Cancer Res. 9 2011 1551 1561
60. H. Sampath, and J.M. Ntambi Role of stearoyl-CoA desaturase-1 in skin integrity and whole body energy balance J. Biol. Chem. 289 2014 2482 2488
61. H. Sampath, M.T. Flowers, X. Liu, C.M. Paton, R. Sullivan, and et al. Skin specific deletion of stearoyl-CoA desaturase-1 alters skin lipid composition and protects mice from high fat diet-induced obesity J. Biol. Chem. 284 2009 19961 19973
62. N. Scaglia, and R.A. Igal Stearoyl-CoA desaturase is involved in the control of proliferation, anchorage-independent growth, and survival in human transformed cells J. Biol. Chem. 280 2005 25339 25349
63. R.C. Smallridge, and J.A. Copland Anaplastic thyroid carcinoma: pathogenesis and emerging therapies Clin. Oncol. (R. Coll. Radiol.) 22 2010 486 497
64. S. Sun, Z. Zhang, V. Raina, N. Pokrovskaia, D. Hou, R. Namdari, K. Khakh, L.G. Ratkay, D.G. McLaren, M. Mork, J. Fu, S. Ferreira, B. Hubbard, M.D. Winther, and N. Dales Discovery of thiazolylpyridinone SCD1 inhibitors with preferential liver distribution and reduced mechanism-based adverse effects Bioorg. Med. Chem. Lett. 24 2014 526 531
65. S. Sun, Z. Zhang, V. Kodumuru, N. Pokrovskaia, J. Fonarev, Q. Jia, P.-Y. Leung, J. Tran, L.G. Ratkay, D.G. McLaren, C. Radomski, S. Chowdhury, J. Fu, B. Hubbard, M.D. Winther, and N.A. Dales Systematic evaluation of amide bioisosteres leading to the discovery of novel and potent thiazolylimidazolidinone inhibitors of SCD1 for the treatment of metabolic diseases Bioorg. Med. Chem. Lett. 24 2014 520 525
66. S. Sun, Z. Zhang, N. Pokrovskaia, S. Chowdhury, Q. Jia, E. Chang, K. Khakh, R. Kwan, D.G. McLaren, C.C. Radomski, L.G. Ratkay, J. Fu, N.A. Dales, and M.D. Winther Discovery of triazolone derivatives as novel, potent stearoyl-CoA desaturase-1 (SCD1) inhibitors Bioorg. Med. Chem. 23 2015 455 465
67. J.P. Sundberg, D. Boggess, B.A. Sundberg, K. Eilertsen, S. Parimoo, M. Filippi, and StennK Asebia-2J (Scd1ab2J): a new allele and a model for scarring alopecia Am. J. Pathol. 156 2000 2067 2075
68. H. Takahashi, R. Nakayama, S. Hayashi, N. huhei, T. emoto, Y. Murase, K. Nomura, T. Takahashi, K. Kubo, S. Marui, K. Yasuhara, T. Nakamura, T. Sueo, A. Takahashi, K. Tsutsumiuchi, T. Ohta, A. Kawai, S. Sugita, S. Yamamoto, T. Kobayashi, H. Honda, T. Yoshida, and T. Hasegawa Macrophage migration inhibitory factor and stearoyl-CoA desaturase 1: potential prognostic markers for soft tissue sarcomas based on bioinformatics analyses PLoS One 8 2013 e78250
69. I. Tanida, T. Ueno, and E. Kominami LC3 and Autophagy Methods Mol. Biol. 445 2008 77 88
70. H. Tilg, and A.R. Moschen Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis Hepatology 52 2010 1836 1846
71. S. Uryu, S. Tokuhiro, and T. Oda β-Amyloid-specific upregulation of stearoyl coenzyme A desaturase-1 in macrophages Biochem. Biophys. Res. Commun. 303 2003 302 305
72. Y. Uto, T. Ogata, Y. Kiyotsuka, Y. Ueno, Y. Miyazawa, H. Kurata, T. Deguchi, N. Watanabe, M. Konishi, R. Okuyama, N. Kurikawa, T. Takagi, S. Wakimoto, and J. Ohsumi Novel benzoylpiperidine-based stearoyl-CoA desaturase-1 inhibitors: identification of 6-[4-(2-methylbenzoyl) piperidin-1-yl]pyridazine-3-carboxylic acid (2-hydroxy-2-pyridin-3-ylethyl) amide and its plasma triglyceride-lowering effects in Zucker fatty rats Bioorg. Med. Chem. Lett. 20 2010 341 345
73. C.A. von Roemeling, L.A. Marlow, J.J. Wei, S.J. Cooper, T.R. Caulfield, K. Wu, W.W. Tan, H.W. Tun, and J.A. Copland Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma Clin. Cancer Res. 19 2013 2368 2380
74. C.A. von Roemeling, L.A. Marlow, A.B. Pinkerton, A. Crist, J. Miller, H.W. Tun, R.C. Smallridge, and J.A. Copland Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target J Clin Endocrinol Metab February 2015 jc20142764. (Epub ahead of print)
75. J. Wang, L. Yu, R.E. Schmidt, C. Su, X. Huang, K. Gould, and G. Cao Characterization of HSCD5, a novel human stearoyl-CoA desaturase unique to primates Biochem. Biophys. Res. Commun. 332 2005 735 742
76. G. Waris, D. Felmlee, F. Negro, A. Siddiqui, and C. Hepatitis virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress J. Virol. 81 2007 8122 8130
77. Xenon Pharmaceuticals Web Site. 2015. Available from: http://www.xenon-pharma.com/product-candidates/dermatologic/ (accessed 25.08.15.).
78. Z. Xin, H. Zhao, M.D. Serby, B. Liu, M. Liu, B.G. Szczepankiewicz, L.T. Nelson, H.T. Smith, T.S. Suhar, R.S. Janis, N. Cao, H.S. Camp, C.A. Collins, H.L. Sham, T.K. Surowy, and G. Liu Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors Bioorg. Med. Chem. Lett. 18 2008 4298 4302
79. T. Yamashita, M. Honda, H. Takatori, R. Nishino, H. Minato, H. Takamura, T. Ohta, and S. Kaneko Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma J. Hepatol. 50 2009 100 110
80. S.-M. Yang, Y. Tang, R. Zhang, H. Lu, G.-H. Kuo, M.D. Gaul, Y. Li, G. Ho, J.G. Conway, Y. Liang, J.M. Lenhard, K.T. Demarest, and M.W.V. urray 4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable Stearoyl-CoA desaturase-1 (SCD1) inhibitors. Part 1: urea-based analogs Bioorg. Med. Chem. Lett. 23 2013 6773 6776
81. S.-M. Yang, Y. Tang, T. Rano, H. Lu, G.-H. Kuo, M.D. Gaul, Y. Li, G. Ho, W. Lang, J.G. Conway, Y. Liang, J.M. Lenhard, K.T. Demarest, and W.V. Murray 4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: pyridazine-based analogs Bioorg. Med. Chem. Lett. 24 2014 1437 1441
82. L. Zhang, L. Ge, S. Parimoo, K. Stenn, and S.M. Prouty Human stearoyl-CoA desaturase alternative transcripts generated single gene tandem polyadenylation sites Biochem. J. 340 1999 255 264
83. Z. Zhang, S. Sun, V. Kodumuru, D. Hou, S. Liu, N. Chakka, S. Sviridov, S. Chowdhury, D.G. McLaren, L.G. Ratkay, K. Khakh, X. Cheng, H.W. Gschwend, R. Kamboj, J. Fu, and M.D. Winther Discovery of piperazin-1-ylpyridazine-based potent and selective stearoyl-CoA desaturase-1 inhibitors for the treatment of obesity and metabolic syndrome J. Med. Chem. 56 2013 568 583
84. Z. Zhang, N.A. Dales, and M.D. Winther Opportunities and challenges in developing stearoyl-coenzyme A desaturase-1 inhibitors as novel therapeutics for human disease J. Med. Chem. 57 2014 5039 5056
85. Y. Zheng, K.J. Eilertsen, L. Ge, L. Zhang, J.P. Sundberg, S.M. Prouty, K.S. Stenn, and S. Parimoo Scd1 is expressed in sebaceous glands and is disrupted in the asebia mouse Nat. Genet. 23 1999 268 270
86. C.C. Zouboulis Acne and sebaceous gland function Clin. Dermatol. 22 2004 360 366